

Change order details by crossing out unwanted information and writing in desired details/instructions. Place a line through the \boxtimes to remove the pre-checked option.

| Infusio | n Center Location: | | Start Date: | | | |
|--|---|--|-------------|-----------------|-------------------------------|--|
| Diagno | osis/Indication: | | | | | |
| Author | ization Number: | | | | | |
| | t Name | | | | | |
| Supp | oortive Care | | Interval | | | |
| | | | Route: | | | |
| Starting when released, For 1 dose, DOSING WILL BE ROUNDED TO NEAREST VIAL SIZE. Use an non-pyrogenic, low protein-binding filter with 1.2 micron pore size or less. Infuse 10ml/hr x15min; then x15min; then 40ml/hr x15min; then 80ml/hr x15min; then 150ml/hr x15min; then max 250ml/hr until do Dose Frequency | | | | | x15min; then 20ml/hr | |
| | INFLIXIMAB-DYYB IVPB | | | Route: | | |
| | non-pyrogenic, low protein-binding filter w x15min; then 40ml/hr x15min; then 80ml/h | rting when released, For 1 dose, DOSING WILL BE ROUNDED TO NEAREST VIAL SIZE. Use an in-line, sterile -pyrogenic, low protein-binding filter with 1.2 micron pore size or less. Infuse 10ml/hr x15min; then 20ml/hr min; then 40ml/hr x15min; then 80ml/hr x15min; then 150ml/hr x15min; then max 250ml/hr until done. se Frequency | | | | |
| | INFLIXIMAB-ABDA IVPB | | | Route: | | |
| | Starting when released, For 1 dose, DOSING WILL BE ROUNDED TO NEAREST VIAL SIZE. Use an in-line, sterile non-pyrogenic, low protein-binding filter with 1.2 micron pore size or less. Infuse 10ml/hr x15min; then 20ml/hr x15min; then 40ml/hr x15min; then 80ml/hr x15min; then 150ml/hr x15min; then max 250ml/hr until done. Dose Frequency | | | | | |
| Labs | | | Interval | | | |
| | Complete Blood Count with Automated D | Differential | Once | | | |
| | Starting when released | | | | | |
| | Comprehensive Metabolic Panel | | Once | | | |
| | Starting when released | | | | | |
| | Treatment Lab Instructions | | PRN | | | |
| | Starting when released Nursing to release the following labs: -CBC with Differential, -CMP, Provider approves to Release and Draw labs 2 days Pre & Post this Planned Treatment Date. Draw labs *** every 3 months ** or *** every 6 months *** unless patient has had lab drawn in the last 4 weeks. Provider will need to address the frequency of lab draws. | | | | | |
| Prov | ider Communication Orders | | Interval | | | |
| | Provider Communication | | PRN | | | |
| | Starting when released Ordering physician/provider has screened this patient for history of chronic infection, heart failure, seizure disorder, liver disease, tuberculosis, blood dyscrasias, hepatitis (hepatits B surface antiger and hepatitis B core antibody), or malignancy prior to initiation of InFLIXimab (Remicade®) or biosimilar equivalent therapy. | | | | | |
| | Provider Communication | | Once | | | |
| | Starting when released Select most a central line access set of orders, then | | | for IV access / | central line - if selecting a | |
| | Provider Signature | EHR Use | er ID Date | | Time | |
| nitials | - | | | | | |
| | | Page 1 | of 3 | FHR | 1927-DT (02/14/2024) | |
| | | - | | | TENANCE INFUSION | |
| Diago Dationt Labor Liona | | | | | | |
| | Place Patient Label Here | | | Prog & Or | - | |

| Nursi | ng Orders | Interval | | | |
|-------|---|-----------------|-----------|--|--|
| | Nursing Communication | Every visit | | | |
| | Starting when released Infusion # 1-4: vitals prior to infusion, before each rate increase, 30 minutes following infusion. Observe patient 30 minutes after completion of infusion. Infusion # 5-8: vitals prior to infusion, 30 minutes after initiation, at end of infusion, and 30 minutes following infusion. Observe patient 30 minutes after completion of infusion, at end of infusion infusion, at end of infusion, and 30 minutes following infusion. Observe patient 30 minutes after completion of infusion, at end of infusion infusion, at end of infusion of infusion, at end of infusion of infusion and encoded of the serve patient 30 minutes after completion of infusion. Infusion #10 & beyond: vitals prior to infusion and encoded of infusion. No observation required upon completion of infusion. | | | | |
| | Insert peripheral IV | PRN | | | |
| | Starting when released | | | | |
| | Access & Use Central Line/CVAD | PRN | | | |
| | Starting when released Access vascular device and confirm patency. | | | | |
| | Access & Use Central Line/CVAD | PRN | | | |
| | Starting when released Access vascular device and confirm patency. | | | | |
| | sodium chloride (NS) flush 10 mL | PRN | Route: IV | | |
| | Line Care, Starting when released | | | | |
| | Initiate Central Line (Non-PICC) Maintenance Protocol | PRN | | | |
| | Starting when released | | | | |
| | Initiate PICC Maintenance Protocol | PRN | | | |
| | Starting when released | | | | |
| | sodium chloride 0.9 % injection 10 mL | PRN | Route: IV | | |
| | Other, Line Care prior to medication administration, Starting when released | | | | |
| | Nursing Communication | PRN | | | |
| | Starting when released Change PICC line dressing weekly and as needed. | | | | |
| | sodium chloride 0.9 % injection 10 mL | PRN | Route: IV | | |
| | Other, Line Care post medication administration, Start | ing when releas | sed | | |
| | sodium chloride 0.9 % injection 10 mL | PRN | Route: IV | | |
| | Other, Line Care prior to medication administration, Starting when released | | | | |
| | sodium chloride 0.9 % injection 20 mL | PRN | Route: IV | | |
| | Other, Line Care post lab draw, Starting when released | | | | |
| | sodium chloride 0.9 % injection 10 mL | PRN | Route: IV | | |
| | Other, Line Care post medication administration, Starting when released | | | | |
| | sodium chloride 0.9 % injection 10 mL | PRN | Route: IV | | |
| | Other, Line Care at discharge and de-access, Starting when released | | | | |
| | sodium chloride 0.9 % injection 20 mL | PRN | Route: IV | | |
| | Other, Line Care post lab draw, Starting when released | | | | |
| | heparin, porcine (PF) 100 unit/mL flush 500 Units | PRN | Route: IV | | |
| | Line Care, for de-access, Starting when released | | | | |

| Provider Signature | EHR User ID | Date | Time | |
|--------------------------|---------------|----------------|-------------------------|--|
| Initials | | | | |
| | Page 2 of 3 | | EHR1927-DT (02/14/2024) | |
| | INFLIXIMA | B OR BIOSIMILA | R MAINTENANCE INFUSION | |
| Place Patient Label Here | Prog & Orders | | | |

| Place Patient Label Here | | Prog & Orders | | | |
|--|--|--|--|--|--|
| | | - | SIMILAR MAINTENANCE INFUSION | | |
| | | Page 3 of 3 | EHR1927-DT (02/14/2024) | | |
| Initials | | LIN USEI D Dale | 111110 | | |
| | Provider Signature | EHR User ID Date | Time | | |
| 0.5 mg Once As Needed Intramuscular Other, For severe drug reaction (flushing, dizziness, headache diaphoresis, fever, palpitations, chest discomfort plus blood pressure changes (>/= 40 points in SBP), s of breath with wheezing and O2Sat <90%), and notify provider, For 1 dose | | | | | |
| | EPINEPHrine (ADRENALIN) injection 0.5 mg | PRN | Route: Intramuscular | | |
| | 125 mg Once As Needed IV For shortness of breath for continued symptoms of mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>/= 20 points in SBP), nausea, urticaria, chills, pruritis) that worsen or persist after administration of diphenhydramine (Benadryl), and notify provider, Starting when released, For 1 dose | | | | |
| | methylPREDNISolone sodium succinate (Solu- MEDROL) injection 125 mg | PRN | Route: IV | | |
| | 2 puff Once As Needed Inhalation Wheezing, Shortness of Breath, wheezing, shortness of breath associated with infusion reaction and notify provider, Starting when released, Administer with a spacer if available. | | | | |
| | albuterol 90 mcg/actuation inhaler 2 puff | PRN | Route: Inhalation | | |
| | 25 to 50 mg Once As Needed IV Other, For mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>/= 20 points in SBP), nausea, urticaria, chills, pruritis), For 1 dose, Administer 50 mg IV if patient has NOT had diphenhydramine within 2 hours of reaction. Administer 25 mg IV if patient has had diphenhydramine within 2 hours of reaction, if reaction doesn't resolve in 3 minutes may repeat 25mg IV dose for a total of 50 mg, and notify provider | | | | |
| | diphenhydrAMINE (BENADRYL) injection 25-5 | 0 mg PRN | Route: IV | | |
| Emer | gency Medications | Interval | | | |
| | 500 mL Once As Needed IV Line Care, Star | rting when released, Run a | t TKO (25ml/hr) | | |
| | sodium chloride 0.9 % bolus 500 mL | PRN | Route: IV | | |
| | 10 mL As Needed IV Line Care, Starting wh | | | | |
| | sodium chloride (NS) flush 10 mL | PRN | Route: IV | | |
| PRN | Medications | Interval | | | |
| | methylPREDNISolone sodium succinate (Solu- MEDROL) injection 40 mg Once Starting when released, For 1 dose | Every visit | Route: IV | | |
| | Once Starting when released, For 1 dose | | | | |
| | loratadine (CLARITIN) tablet 10 mg | Every visit | Route: Oral | | |
| | Once Starting when released, For 1 dose | | | | |
| | diphenhydrAMINE (BENADRYL) capsule 25 m | g Every visit | Route: Oral | | |
| | Once Starting when released, For 1 dose | - , | | | |
| | acetaminophen (TYLENOL) tablet 650 mg | Every visit | Route: Oral | | |
| Pre-M | Other, Line care, Starting when released, For for injection to vial; let the vial stand undistur completely dissolved (complete dissolution s mg/mL. Retain in catheter for 30 minutes to 2 Iedications | bed to allow large bubbles should occur within 3 minute | to dissipate. Mix by gently swirling until es); do not shake. Final concentration: 1 | | |
| | alteplase (CATHFLO) injection 2 mg | | Route: Intra-Catheter | | |
| | water for injection to vial; let the vial stand un until completely dissolved (complete dissolut concentration: 1 mg/mL. Retain in catheter for | ndisturbed to allow large bu tion should occur within 3 n | bbles to dissipate. Mix by gently swirling ninutes); do not shake. Final still a 2nd dose if occluded. | | |
| | alteplase (CATHFLO) injection 2 mg Other, Line Care, Starting when released, F | PRN | Route: Intra-Catheter | | |
| | | | | | |